leisure time -WSS

leisure time

author：hotspot 2025-09-06 02:12:59 - browse：2647

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ReNAgade cuts staff seven months after raising $300 million

Wikipedia

WSS

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

How generative AI ratchets up security threats for health systems

Wegovy leads to weight loss. Can it treat depression, too?

Readout Newsletter: The latest on Novavax, Merck, Bluebird

FDA investigates CAR

J&J to emphasize cancer drugs, stop much of its vaccine research

hotspot

leisure time

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Venture capital firm's plans to take over Akron hospital face hurdles

What does generative AI mean for health care? We asked experts

The Affordable Care Act has saved billions in health care costs

Peter Hotez and the public health issue of online harassment

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Moonlake's readout produced a cash windfall. Risks remain

10 reasons why health care startups fail

Medicare details structure of new drug price negotiation program

Will the market for weight loss drugs really reach $100 billion?

Wikipedia

Pediatric cancer treatments threatened by a new FDA policy

UnitedHealth’s Optum accused of antitrust violations in California

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Merck, Johnson & Johnson CEOs will testify on high drug prices

UnitedHealth’s Optum accused of antitrust violations in California

J&J to emphasize cancer drugs, stop much of its vaccine research

focus

entertainment

Wikipedia

leisure time